ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination
Long-term follow-up data from the CheckMate-214 study of the nivolumab [...]
ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer
Data from the CheckMate-920 study on the safety and effectiveness [...]
Nivolumab plus ipilimumab for first-line treatment of advanced kidney cancer: Extended 4-year follow-up
Four-year follow up data are now available from the CheckMate [...]
Survival outcomes for patients on ipilimumab plus nivolumab combination therapy
Further results from the ongoing CheckMate 214 phase III study [...]
ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
ASCO 2020: Optimised treatment of advanced kidney cancer with nivolumab and ipilimumab
Two studies were presented during the 2020 American Society of [...]
ASCO GU 2020: Immunotherapy combinations effective for brain metastases
Two small studies reported on patients whose kidney cancer had [...]
Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have [...]
Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer
The combination of nivolumab with ipilimumab has been proven to [...]
